Most active Nasdaq-traded stocks - Yahoo News
The S&P (^GSPC:SNP) again shrugged off the geopolitical worries of Ukraine, the ongoing conflict in Gaza, possible sooner-than-expected rate hikes, and an economy that cant seem to gain top stocks to invest in traction. Itmade its 30th new contract high in 2014 and is now up over 8% on the year and up 38% on the last 20 months. While many market timers and economists continue to remain cautious and compare it tothe 1999-2000 tech bubble, zero borrowing cost and stock buybacks continue to propel the stock market higher. We remember very well how the tech bubble ended but we also seethat comparisons between 2000 and 2014 have not helpedthe short sellers. In the summer of 2000 the big game in town was the day trading stock rooms.
Stocks Poised To Open Higher, Burger King And Tim Hortons In Tie-Up Talks - NASDAQ.com
advanced 2.3%, electronics giant Hitachi, Ltd. rose 1.2%, Internet and telecoms conglomerate SoftBank Corp. improved by 1.1%, and electronics manufacturer Panasonic Corp. zoomed 0.9% higher. Financial stocks also gained, with investment bank Nomura Holdings, Inc.
Japan Stocks Advance On Strong U.S. Cues | Fox Business
fell .1 percent to $33.73 with 13,674,400 shares traded. Microsoft Corp. fell .2 percent to $41.80 with 15,801,200 shares traded. NewLead Holdings Ltd. fell 19.8 percent to $.15 with 25,942,200 shares traded.
In corporate news, Burger King ( BKW ) is in talks to buy Tim Hortons ( THI ) and form a new publicly listed company that would be based in Canada. The deal would make it the world's third-largest fast-food restaurant company. Burger King shares are set to jump 12 percent, while Tim Hortons is up 16 percent pre-market. Swiss drug maker Roche will buy California'sInterMune ( ITMN ) for $8.3 billion.
Story Stocks from Briefing.com - Yahoo Finance
Done Done 8:48 am Silicon Motion +7% pre-market after raising Q2 guidance Silicon Motion ( SIMO ) raised Q2 revenue guidance to +30-32% QoQ, which calculates to approx.$68.7-69.8 mln, well above expectations (from +10-15%). The company also raised gross margin guidance to 51-52% from 48-50%. 8:47 am Spectrum Pharma almost +5% after FDA grants accelerated approval of Beleodaq Spectrum Pharma ( SPPI ) announced that the FDA has granted Accelerated Approval of Beleodaq for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (:PTCL). This indication is approved under accelerated approval based on Tumor Response Rate and Duration of Response.